Sarepta Therapeutics, Inc. (SRPT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 2.3/10 is below the 5.0 floor at $15.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Catalent (ELEVIDYS commercial CMO); Concentration risk — Supplier: Aldevron (plasmid supplier for ELEVIDYS).
Sarepta Therapeutics is a commercial-stage biopharma with four FDA-approved Duchenne muscular dystrophy products (EXONDYS 51, VYONDYS 53, AMONDYS 45, ELEVIDYS), generating $1,864.3M in net revenues in 2025. All products rely on third-party CMOs for manufacturing as Sarepta has... Read more
Sell if holding. Momentum 2.3/10 is below the 5.0 floor at $15.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Catalent (ELEVIDYS commercial CMO); Concentration risk — Supplier: Aldevron (plasmid supplier for ELEVIDYS). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About Sarepta Therapeutics, Inc.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics generated $1,864.3 million in net product revenues in 2025 from four FDA-approved Duchenne muscular dystrophy treatments: EXONDYS 51 (exon 51 skipping, launched 2016), VYONDYS 53 (exon 53 skipping, launched 2019), AMONDYS 45 (exon 45 skipping, launched 2021), and ELEVIDYS, an AAV gene therapy that received traditional FDA approval for ambulatory patients in June 2024 and accelerated approval for non-ambulatory patients the same month.
Sarepta distributes PMO products through a limited home-infusion specialty pharmacy network and a specialty distributor serving hospitals and outpatient clinics; ELEVIDYS flows through third-party logistics providers and a limited specialty pharmacy network for in-hospital infusion. The company currently lacks internal GMP manufacturing capability and relies on Catalent for commercial supply of ELEVIDYS and the SRP-9003 LGMD program, while Aldevron supplies plasmid material for ELEVIDYS and SRP-9003. Reimbursement coverage for ELEVIDYS has been restricted by certain payors following the 2025 safety events, and the ESSENCE confirmatory trial reported topline failure to meet its primary endpoint on November 3, 2025, creating regulatory uncertainty for AMONDYS 45 and VYONDYS 53 under the FDA's accelerated approval pathway. Pipeline programs include SRP-1001 (FSHD) and SRP-1003 (DM1) in Phase 1/2a through the Arrowhead Collaboration Agreement signed in November 2024.
Show full overview
Two simultaneous regulatory pressures compound uncertainty around the product portfolio. The ESSENCE trial for AMONDYS 45 and VYONDYS 53 failed to achieve statistical significance on its primary endpoint, which the 10-K notes could lead to label changes, revocation of accelerated approvals, or directives to remove those products from the market. Concurrently, ELEVIDYS carries a boxed warning for acute liver injury and acute liver failure added in November 2025, with the non-ambulatory indication removed from the Prescribing Information, making resumption of dosing in that population subject to an additional FDA review process dependent on sirolimus immunosuppressant trial data.
See also: Healthcare · Biotechnology
From Sarepta Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Sarepta Therapeutics, Inc.
Latest news
- NEWS Watching Sarepta Therapeutics, Disc Medicine; Shares See Volume To The Upside After WSJ Reports "Trump Planning to Fire — benzinga May 8, 2026 positive
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS Sarepta Therapeutics Q1 Adj. EPS $3.16 Beats $0.99 Estimate, Sales $730.803M Beat $474.155M Estimate — benzinga May 6, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target — benzinga Apr 16, 2026 negative
- NEWS 9 Health Care Stocks With Whale Alerts In Today's Session — benzinga Apr 7, 2026 positive
Generated 2026-06-17T09:12:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierCatalent (ELEVIDYS commercial CMO)10-K Item 1: 'Catalent supports our clinical and commercial manufacturing demand for ELEVIDYS and our SRP-9003 LGMD program'
- HIGHSupplierAldevron (plasmid supplier for ELEVIDYS)10-K Item 1: 'Aldevron provides plasmids for ELEVIDYS and SRP-9003 and is expected to provide plasmid source material for any future gene therapy programs.'
Material Events(8-K, last 90d)
- 2026-02-25Item 5.02HIGHCEO Douglas Ingram notified the Company of his decision to retire as CEO by end of 2026 or upon appointment of his replacement. Search for internal and external candidates commenced. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -1.9% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.3/10 is below the 5.0 floor at $15.75 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Catalent (ELEVIDYS commercial CMO); Concentration risk — Supplier: Aldevron (plasmid supplier for ELEVIDYS). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.63. Score 4.5/10, moderate confidence.
Take-profit target: $19.80 (+25.9% upside). Prior stop was $14.63. Stop-loss: $14.63.
Concentration risk — Supplier: Catalent (ELEVIDYS commercial CMO); Concentration risk — Supplier: Aldevron (plasmid supplier for ELEVIDYS); Weak overall score: 4.5/10.
Sarepta Therapeutics, Inc. trades at a P/E of 43.7 (forward 5.6). TrendMatrix value score: 7.5/10. Verdict: Sell.
33 analysts cover SRPT with a consensus score of 3.4/5. Average price target: $22.
What does Sarepta Therapeutics, Inc. do?Sarepta Therapeutics is a commercial-stage biopharma with four FDA-approved Duchenne muscular dystrophy products...
Sarepta Therapeutics is a commercial-stage biopharma with four FDA-approved Duchenne muscular dystrophy products (EXONDYS 51, VYONDYS 53, AMONDYS 45, ELEVIDYS), generating $1,864.3M in net revenues in 2025. All products rely on third-party CMOs for manufacturing as Sarepta has no internal GMP production capability.